The Daily Toke

March 23, 2026

Across the United States, cannabis policy is accelerating toward a patchwork legalization landscape as some states sprint ahead while others impose sudden restrictions—and a federal reckoning looms for the entire hemp-derived THC market by November. Virginia is moving decisively forward, with lawmakers approving legislation last week to launch a regulated retail cannabis marketplace in 2027, finally creating a legal sales infrastructure five years after the state legalized possession. Meanwhile, Tennessee Democrats introduced the "Pot for Potholes Act," which would legalize recreational marijuana for adults 21 and older while dedicating a 15% state tax on cannabis sales to highway infrastructure repair—a pragmatic framing that ties drug policy to fiscal priorities. 💰 MONEY MOVES Louisiana is exploring a limited adult-use pilot program running through 2030, though critics argue the structure reinforces an existing duopoly controlled by two private operators, with Good Day Farm and Ilera Holistic Healthcare locked into exclusive licenses. Idaho activists have collected enough signatures to qualify a medical cannabis measure for the November ballot, though validity questions remain about the petition signature distribution across regions.

The political momentum is unmistakable at the state level, but it's colliding with mounting pressure from federal restrictions. 💰 MONEY MOVES A pending federal policy change set to take effect in November would effectively eradicate the hemp-derived THC products industry—a market worth an estimated $28.4 billion—by redefining hemp to ban products with more than 0.4 milligrams of THC per container. Rep. James Comer (R-KY), chairman of the House Oversight and Government Reform Committee, is urging Congress to delay these restrictions, but the uncertainty has already triggered state-level regulatory scrambling. Pennsylvania amended its cannabis regulation bill to mirror the pending federal hemp restrictions, banning most intoxicating hemp products while establishing a Cannabis Control Board to oversee both medical cannabis and hemp-derived products. Ohio has already moved, with Senate Bill 56 taking effect March 20, banning THC beverages, restricting hemp products to 0.4 milligrams of THC per container, and rolling back protections for recreational marijuana consumers approved by voters in 2023—a move that prompted lawsuits from breweries and triggered a failed referendum effort by Ohioans for Cannabis Choice.

Across multiple states, regulatory bodies are also signaling openness to cannabis normalization beyond traditional smoking and flower. Massachusetts lawmakers approved legislation to create psilocybin pilot programs for eligible patients, acknowledging therapeutic applications of psychedelics in a clinical framework. New York's Senate Health Committee approved a bill on medical cannabis reciprocity for out-of-state patients and pre-rolled joints—measures that are technically already allowed under state law, suggesting the bill is more about clarification and formal endorsement. 🚀 THIS IS COOL The WNBA and its players' union agreed to end marijuana testing in a collective bargaining agreement, removing the sport's testing requirement entirely—a significant symbolic shift for a major professional league that acknowledges cannabis is no longer a performance or integrity issue worth monitoring. Indiana Gov. Mike Braun (R) acknowledged that the state will "probably have to address" marijuana legalization to avoid "lagging behind neighboring states" as reform spreads across the Midwest and Great Lakes regions.

The federal definition change scheduled for November represents an inflection point that's forcing states to choose between alignment with incoming federal law and preserving existing markets. Pennsylvania's move to preemptively ban most hemp THC products aligns with federal policy while creating the regulatory infrastructure for eventual adult-use legalization—positioning the state to move faster once federal restrictions take effect. Louisiana's cautious pilot program approach may actually shield the state from federal enforcement pressure while testing market dynamics with limited scope. Ohio's aggressive restrictions, meanwhile, have already triggered litigation and public backlash, demonstrating the political cost of rolling back voter-approved measures. 🤔 THINK ABOUT IT If the federal government is restricting hemp-derived THC products to near-zero levels while alcohol remains completely legal—and alcohol kills nearly 100,000 Americans annually—what public health rationale actually justifies the disparity?

March 23, 2026

Multiple states are moving simultaneously to restrict or regulate hemp-derived THC products, marking a significant shift in how intoxicating cannabis compounds are treated across the country. On March 20, Ohio's Senate Bill 56 took effect, banning the sale of intoxicating hemp products outside licensed dispensaries—a sweeping change that prohibits sales in gas stations, convenience stores, and smoke shops while capping THC content at 0.4 milligrams per container and explicitly banning delta-8 and other hemp-derived compounds. The same day, South Carolina's Senate passed comprehensive hemp regulations that allow limited sales of low-dose THC drinks and gummies, but only through liquor stores and retail locations with age restrictions and strict packaging requirements. Pennsylvania has amended its cannabis regulation bill to include hemp bans aligned with a pending federal policy change scheduled for November, while Rhode Island's Cannabis Control Commission recommended banning THC drinks from venues with liquor licenses. The convergence of these state-level actions reflects growing frustration with what lawmakers describe as a regulatory "Wild West" created by the 2018 Farm Bill's hemp legalization.

The regulatory split reveals fundamental disagreement about whether prohibition or controlled sales better serve public health. Ohio Governor Mike DeWine framed the ban as necessary to protect minors, arguing "we know it's harmful to kids, we know it's readily available." Pennsylvania Senator Dan Laughlin similarly cited the need to "close loopholes" and prevent "intoxicating hemp products flooding the marketplace with little oversight." But South Carolina's Senate Majority Leader Shane Massey took the opposite approach: "If we're not going to ban it, then I want to regulate it," he said, pushing for "strong and workable" rules rather than prohibition. Business owners warn of unintended consequences—Ohio CBD retailer Adam Southward flagged confusion over how the state defines a "container," creating uncertainty about product compliance. 💰 MONEY MOVES South Carolina hemp industry advocates warned that stricter regulations could shut down approximately 6,000 businesses and eliminate thousands of jobs, according to Dennis Willard, spokesman for Ohioans for Cannabis Choice. The regulatory pendulum swings sharply depending on state, leaving consumers and entrepreneurs facing radically different legal landscapes across state lines.

Federal policy shifts are driving much of this state-level activity. A Congressional Research Service report updated lawmakers on marijuana rescheduling efforts, noting that while the Biden administration recommended moving cannabis from Schedule I to Schedule III, President Trump's executive order to complete the process "hasn't materialized yet." The report also noted changes to hemp policy "set to take effect later this year"—specifically referencing the November federal hemp redefinition that Pennsylvania and other states are moving to align with. 🤔 THINK ABOUT IT Here's the core tension: states are banning or restricting a product with zero recorded overdose deaths in human history, while alcohol—which kills approximately 95,000 Americans annually—remains fully legal and widely available. Prescription opioids kill over 16,000 Americans per year. Cannabis kills zero. Yet regulators cite "public health and safety" as justification for restrictions that mirror or exceed regulations on those far deadlier substances.

The impact on medical users and veterans remains largely absent from these policy debates. Many Americans use legal THC products for PTSD, chronic pain, and anxiety—conditions particularly common among veterans. When states eliminate retail availability, patients who've found relief face a return to unregulated markets or limited options. Pennsylvania Representative Manny Guzman described the current landscape bluntly: "It's like the wild west," he said. "There's no legitimate testing and labeling of products, no age restrictions, no enforcement mechanisms." Guzman highlighted that smoke shops exploit gray areas between federal and state law by selling products they call "hemp" that could be anything—"could be weed, could be K2, could be Delta 9. God knows what's in there." The irony is sharp: states pursuing bans claim to address consumer safety, yet doing so may push consumers toward truly unregulated products rather than toward tested, labeled alternatives.

Pennsylvania lawmakers are still negotiating the path forward. Governor Josh Shapiro included marijuana legalization in his recent budget proposal, which would require figuring out regulation, taxation, and testing statewide. Senator Judy Schwank, who drafted a Delta-8 ban bill in 2022 that stalled, is looking at new legislation and emphasizes that legitimate regulation requires "testing and labeling of products, age restrictions, and stiffer fines and penalties for breaking the law." The federal hemp reclassification coming in November will likely accelerate state action—Pennsylvania's amendment to Senate Bill 49, which creates a Cannabis Control Board to oversee medical cannabis and hemp products, now has clearer federal benchmarks to align with. What remains unclear is whether bans or regulation better achieve the stated goal of keeping intoxicating products from minors while preserving access for adults who use them responsibly or therapeutically. The answers emerging from Ohio, South Carolina, Pennsylvania, and Rhode Island will likely shape federal policy conversations for years.

March 23, 2026

Researchers at East China University of Science and Technology have discovered that powder-based formulations dramatically outperform oil-based systems for CBD stability, with findings published in the Journal of Pharmaceutical and Biomedical Analysis. 🚀 THIS IS COOL The cyclodextrin-based powder (HP-β-CD) retained over 90% of CBD under standard conditions compared to roughly 20% retention in oil when exposed to light, and maintained 86-87% retention at elevated temperatures versus significant breakdown in oil formulations. The powder system also generated fewer unwanted degradation byproducts—staying below 1% compared to as high as 6.2% in oil-based products. This matters because CBD is particularly sensitive to light, heat, and oxygen, all of which can reduce potency and create unintended compounds over time. The findings suggest that encapsulating CBD in cyclodextrin-based powder could significantly extend shelf life and improve product consistency across medical and consumer markets.

However, a major counterpoint has emerged from the largest systematic review of cannabis research ever conducted. Australian researchers analyzing 54 randomized controlled trials over the past 45 years, published in The Lancet Psychiatry, found little to no high-quality evidence that medicinal cannabis effectively treats anxiety, depression, PTSD, or psychotic disorders—conditions that account for six of the top ten reasons cannabis is prescribed. The analysis included data from nearly 2,500 patients, but for some conditions like depression, not a single rigorous trial existed. Jack Wilson, who led the review at the University of Sydney's Matilda Centre for Research in Mental Health and Substance Use, told NPR that "in the absence of evidence at this time, the routine use of medical cannabis products really should be rarely justified for the treatment of mental health disorders."

The gap between public use and scientific evidence is striking. Around 700,000 Australians have used medicinal cannabis in the past year, and sales have increased four-fold since 2022—yet the majority of products prescribed in the Australian market are not registered with the Therapeutic Goods Administration and therefore have not been rigorously tested. The review did identify one promising finding: medicinal cannabis may help reduce cannabis use among those with cannabis use disorder, likely because CBD-THC oral formulations reduce cravings. But for the most common mental health applications driving prescriptions today, the evidence simply isn't there. CBD is non-intoxicating and generally safe, while THC carries documented short-term risks like paranoia and longer-term associations with cannabis use disorder development.

🤔 THINK ABOUT IT The disconnect between what people are using cannabis for and what science actually supports raises important questions about how medical products get prescribed. If we're going to normalize cannabis—and the zero recorded overdose deaths in human history versus 95,000 annual alcohol deaths and 16,000+ prescription opioid deaths suggest we should be having serious conversations about that—then rigorous clinical trials need to catch up with real-world use. The formulation science is advancing rapidly, showing we can make better, more stable products. But without robust evidence on efficacy for mental health conditions, patients and prescribers are operating in a gray zone.

March 23, 2026

Texas hemp businesses face a narrow window to overhaul their operations before sweeping new regulations take effect March 31, eliminating what industry owners describe as their most profitable product lines entirely. The Texas Department of State Health Services adopted rules in early March that redefine how the state measures legal THC levels by counting THCA—a non-intoxicating compound that converts to delta-9 THC only when heated or smoked—as part of the total THC calculation. This single definitional change effectively bans most smokable hemp products, which represent 50 to 70 percent of sales for many retailers across San Antonio, Austin, and San Angelo.

💰 MONEY MOVES The financial shock compounds the regulatory blow. Annual licensing fees are skyrocketing from $155 to $5,000 for retailers and from $258 to $10,000 for manufacturers—a staggering increase of more than 3,000 percent. Allen Kirk, managing partner of Full Spectrum in San Angelo, describes the fee hike as steeper than many alcohol licenses, while simultaneously being told that 35 to 50 percent of current inventory must vanish from shelves within weeks. "Imagine being a business and finding out that not only are your registration fees going up significantly, but also 50 percent—maybe even 70 percent—of the products that you sell now have to be taken off the shelves in a matter of weeks," said Heather Fazio, director of the Texas Cannabis Policy Center. Industry observers warn that some flower-focused retailers are already closing their doors rather than attempt the transition.

The timeline itself has drawn criticism from industry experts, who note that the rules received approval only on March 2—giving businesses just 29 days to comply. The Texas Department of State Health Services reviewed input from over 1,400 public commenters before adopting the rules, with supporters arguing the changes would improve consumer safety and industry oversight. However, there was no grace period built in for retailers to clear non-compliant inventory or restructure their business models. Other non-smokable products including gummies, edibles, creams, and topicals that meet the new THC limits will remain legal and available.

Beyond the immediate market shock, hemp business owners raise concerns about unintended public health consequences. Veterans and other customers rely on smokable THCA products specifically because they provide faster symptom relief than edibles—gummies and oils can take 45 minutes to 90 minutes to take effect, while inhaled products work within minutes. Kirk points out that removing THCA products could push some customers toward unregulated alternatives. "Customers are going to go back to the street. They're going to buy sketchy products from sketchy individuals," he said. The new rules also mandate stricter age verification requirements, expanded product testing protocols, tighter packaging guidelines, and enhanced recordkeeping—regulatory measures that supporters say close loopholes but that critics argue arrived with insufficient transition time.

🤔 THINK ABOUT IT Texas avoided an outright THC ban during last year's legislative session after Governor Greg Abbott vetoed a complete prohibition and instead ordered the health department to review its regulations. The resulting rules don't technically ban THC products outright, but the THCA redefinition effectively eliminates the smokable market. Meanwhile, alcohol—which kills approximately 95,000 Americans annually—remains freely available, and prescription opioids, which kill over 16,000 people per year, face far less restrictive licensing and regulatory frameworks. Cannabis, with zero recorded overdose deaths in human history, now carries licensing fees higher than alcohol in Texas and faces a de facto product ban based on how a non-psychoactive compound is classified. Retailers have until March 31 to comply.